
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate ...
Monte Rosa Therapeutics Inc. GLUE on Thursday revealed clinical results from its MRT-6160 Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study. The study objectives were to evaluate safety, tolerability, pharmacokinetics and …